Abstract Rationale: In cell culture systems, agonists can promote the phosphorylation and internalization of receptors coupled to G proteins (GPCR), leading to their desensitization. However, in the CNS opioid agonists promote a profound desensitization of their analgesic effects without diminishing the presence of their receptors in the neuronal membrane. Recent studies have indicated that CNS proteins of the RGS family, specific regulators of G protein signalling, may be involved in mu-opioid receptor desensitization in vivo. Objective: In this work we review the role played by RGS proteins in the intensity and duration of the effects of mu-opioid receptor agonists, and how they influence the delayed tolerance that develops in response to specific doses of opioids. Results: RGS proteins are GTPase-activating proteins (GAP) that accelerate the hydrolysis of GαGTP to terminate signalling at effectors. The GAP activity of RGS-R4 and RGS-Rz proteins restricts the amplitude of opioid analgesia, and the efficient deactivation of GαzGTP subunits by RGS-Rz proteins prevents mu receptor desensitization. However, RGS-R7 proteins antagonize effectors by binding to and sequestering mu receptor-activated Gαi/o/z subunits. Thus, they reduce the pool of receptor-regulated G proteins and hence, the effects of agonists. The delayed tolerance observed following morphine administration correlates with the transfer of Gα subunits from mu receptors to RGS-R7 proteins and the subsequent stabilization of this association. Conclusion: In the CNS, the RGS proteins control the activity of mu opioid receptors through GAP-dependent (RGS-R4 and RGS-Rz) as well as by GAP-independent mechanisms (RGS-R7). As a result, they can both antagonize effectors and desensitize receptors under certain circumstances.
Introduction
Opioids such as morphine are very efficient in controlling nociceptive sensations and are the analgesics of choice in the treatment of high-intensity chronic pain. Unfortunately, these positive attributes are shadowed by the loss of potency that accompanies their repeated administration. This is a common characteristic of opioids that act via mu receptors and it is a serious drawback for their long-term clinical use in the treatment of severe pain. In experimental paradigms, desensitization of mu receptors can be observed after three consecutive administrations of the same analgesic dose , and even after a single dose of the opioids if this is sufficiently large (Huidobro et al. 1976; .
The opioid receptors that belong to the family of seven transmembrane G-protein-coupled receptors (GPCR) are heavily N-glycosylated proteins (Lui-Chen et al. 1993; Garzón et al. 1995) and regulate Gi/o/z/q/11 transducer proteins (see references in Garzón et al. 2000 ) through a direct interaction (Georgoussi et al. 1995; ChaleckaFranaszek et al. 2000) . The phosphorylation of intracellular residues followed by internalization of the receptors is the most widely accepted mechanism of GPCR desensitization. Thus, upon agonist challenge and the release of activated GαGTP subunits, GPCRs are phosphorylated by Gβ-bound G-protein receptor kinases (GRKs), which is followed by arrestin binding (Lefkowitz 1998) . This process has been amply documented for the mu, delta and kappa opioid receptors in cultured cell systems (see, e.g. Chavkin et al. 2001) , where the desensitization and internalization of mu receptors has been shown to be agonist-dependent. -ol]-enkephalin (DAMGO) promote mu receptor phosphorylation and β-arresting/dynamin-dependent internalization, a number of reports describe the ability of mor-phine to activate the MAP kinase pathway without causing such effects (Arden et al. 1995; Zhang et al. 1998; Schmidt et al. 2000) .
In the CNS, opioid agonists are barely capable of downregulating mu receptors. Although agonist-selective downregulation of mu receptors in neurons can occur, it is usually achieved at doses of agonist greater than those that induce opioid desensitization. Binding studies indicate that in this tissue, strong tolerance to morphine and related opioids such as heroin appears to develop through a reduction in the affinity of the mu agonists for their receptors (Werling et al. 1989; Buzas et al. 1996; Keith et al. 1996; Sternini et al. 1996; Bohn et al. 2000; Finn and Whistler 2001; Garzón et al. 2005a) . Chronic agonist-induced desensitization of kappa-opioid receptors is associated with phosphorylation and no loss of receptors occurs. Nevertheless, recovery from this desensitization does require replacement with newly synthesized receptors rather than dephosphorylation (McLaughlin et al. 2004) . It is also thought that mu receptor substitution is required to overcome chronic morphine-induced desensitization in the mouse brain . Therefore, it appears that molecular mechanisms responsible for receptor desensitization independent of downregulation do exist. In recent years, a series of signalling transduction elements have been implicated in receptor desensitization, suggesting that this phenomenon is a cell membrane-limited process. Indeed, desensitization of mu receptors can be influenced by agents that act on G proteins , either through the RGS proteins that specifically regulate activated Gα subunits (Garzón et al. , 2004 Sánchez-Blázquez et al. 2003; Zachariou et al. 2003) or through the phosducinlike proteins that regulate of Gβγ dimers (Garzón et al. 2002) .
While the mu, delta and kappa receptors activate the Gi/o and Gq/11 proteins, mu receptor signalling is closely linked to the Gz proteins Standifer et al. 1996; Garzón et al. 1997a,b; Belcheva et al. 2000) . The situation is further complicated by the fact that agonists display different affinities to the mu receptors depending on whether they are coupled to Gi, Go or Gz proteins (Garzón et al. 1998; Stanasila et al. 2000; Massotte et al. 2002) . Moreover, this coupling also determines the pattern of G protein activation by the agonist (see and references therein). Over and above receptorspecific coupling to G protein classes and the capacity of agonists to determine which G proteins are activated, the regulation of the resulting GαGTP subunits and Gβγ dimers clearly determine the potency and duration of the agonist effects. Theoretically, a cell must rapidly adapt to the intensity of the signals that originate through the recognition of extracellular messengers. This depends on the existence of efficient regulatory mechanisms to synchronize both these phenomena. In this sense, the RGS proteins attempt to coordinate the variations in agonist-induced GPCR activation with the regulation of the target effectors. In certain circumstances the receptor-activated GαGTP subunits reach and regulate their effectors before they bind to RGS proteins. This is indeed the case for RGS9-1 proteins that act on GαtGTP subunits only when they are bound to the effector, the γ subunit of cGMP phosphodiesterase (Skiba et al. 2000) . The RGS-GαGTP interaction accelerates the hydrolysis of GαGTP into GαGDP, thereby terminating Gα signalling at the effector (Berman and Gilman 1998; Hepler 1999) . The subsequent binding of the effector-inactive GαGDP subunits to Gβγ dimers suspends the effector regulation exerted by the latter. The reconstituted trimeric G proteins refill the pool of the receptor-regulated G proteins that is required for the agonists to transmit their signals when present in the receptor environment.
Therefore, by accelerating GαGTP hydrolysis, RGS proteins maintain the equilibrium between agonist-induced receptor activation and the number of GαGTP subunits that regulate the effectors (Berman et al. 1996b) . Moreover, upon dissociation of the agonist from the receptor, RGS proteins are responsible for rapidly extinguishing G protein signals to the effector (Doupnik et al. 1997) . Here, the role of RGS proteins on agonist provoked desensitization of neural mu-opioid receptors will be reviewed.
Characteristics of the RGS proteins
To date, more than 30 distinct proteins that contain an RGS or an RGS-like domain have been described. The RGS proteins are GAPs for the α subunits of heterotrimeric Gi, Go, Gz, Gt and Gq proteins and they differ significantly in size, amino acid sequence and tissue distribution. Their GAP activity is mediated through an evolutionary conserved region of approximately 130 amino acids which is organized into nine α-helices that fold into two compact globular subdomains (Tesmer et al. 1997; Carman et al. 1999; Longenecker et al. 2001; Zheng et al. 2001) . Based on the amino acid sequence within the conserved RGS domains, these proteins have been classified into four main subfamilies, Rz, R4, R7 and R12 (Zheng et al. 1999; Ross and Wilkie 2000) . Many RGS proteins possess other additional domains that enable them to act as physical scaffolds between different regulatory molecules. In this way, the RGS proteins can couple together independent signalling pathways, or they can be targeted to different subcellular domains to participate in specific molecular interactions (e.g. the cell membrane or the nucleus).
RGS-R4 subfamily
The members of the RGS-R4 subfamily are each encoded by a different gene and are mainly proteins of about 20 to 24 kDa, except for the larger RGS3 (61 kDa; Sierra et al. 2002) . They commonly have an amphipatic helix at the N terminus (RGS1, RGS2, RGS4 and RGS 16) that could serve for membrane anchoring. This is followed by the RGS box and a short C terminus. The RGS3 protein has an extended N-terminal domain of ≈300 residues that distinguishes it from the other members of this subfamily. The expression of the murine RGS-R4 subfamily members (unpublished results) compares satisfactorily with their distri-bution in the rat brain (Shuey et al. 1998; Saitoh et al. 1999; Doupnik et al. 2004) . The majority of the RGS-R4 proteins are GAPs for Gαi/oGTP and Gαq/11GTP but they do not act on GαsGTP subunits. Moreover, they only weakly deactivate GαzGTP proteins (Hepler et al. 1997 ).
RGS-R7 subfamily
In mammals, the RGS-R7 subfamily is encoded by four genes, Rgs6, Rgs7, Rgs9 and Rgs11. These genes are transcribed into multiple mRNAs that produce different isoforms (Rahman et al. 1999; Doupnik et al. 2001; Giudice et al. 2001) . The members of the RGS-R7 subfamily, RGS6, RGS7, retinal RGS9-1 and RGS11, are proteins of about 50 kDa, while the RGS9-2 isoform found in the CNS has a size of about 77 kDa. All these proteins share a similar organization in which the regions flanking the RGS domain contain a DEP domain (Dishevelled, EGL-10, pleckstrin), the R7 homology domain (R7H), and the G-protein γ-subunit-like (GGL) domain (for a review, see Hollinger and Hepler 2002) . While the DEP and probably the R7H domains may be involved in membrane attachment (Axelrod et al. 1998; Sondek and Siderovski 2001) , the GGL domain binds to the Gβ5 protein but not to other Gβ subunits (Snow et al. 1998; Hepler 1999; Zhang and Simonds 2000) . The N-terminus of RGS7 binds to snapin, a protein associated with the SNARE complex in neurons, and this interaction could play a role in synaptic vesicle exocytosis (Hunt et al. 2003) .
In the CNS, the mammalian RGS-R7 proteins are mostly found in the cell membrane although they may also be found in the nucleus (Gold et al. 1997; Thomas et al. 1998; Rose et al. 2000; Zhang and Simonds 2000; Zhang et al. 2001; Burchett 2003) . The RGS-R7 proteins and Gβ5 proteins are always found as dimers in this tissue, indicating that this association is required for the GAP activity on the corresponding GαGTP subunits (Snow et al. 1998; Zhang and Simonds 2000) . Membrane targeting of the RGS7/Gβ5 is a complex process requiring the interaction of the RGS domain with Gαo subunits and the palmitoylation of the RGS protein (Takida et al. 2004) .
Although widely expressed in the nervous system, it appears that members of the RGS-R7 subfamily are preferentially expressed in some regions. The distribution of the RGS-R7 mRNAs in the mouse Zachariou et al. 2003; López-Fando et al. 2005) compares satisfactorily with that reported in the rat brain (Gold et al. 1997; Shuey et al. 1998; Snow et al. 1998; Rahman et al. 1999; Saitoh et al. 1999) . Similarly, mRNA for the RGS-R7 binding protein Gβ5 has also been isolated from the mouse CNS and is mostly found associated with neural membranes (Watson et al. 1996; Sánchez-Blázquez et al. 2003) .
When complexed with Gβ5 proteins, RGS6 and RGS7 proteins display moderate GAP activity on GαoGTP in vitro and weak or undetectable activity on other classes of GαGTP subunits (Posner et al. 1999) . Furthermore, RGS11/ Gβ5 complexes are about 12 times more efficient at increasing GTP hydrolysis via Gαo than via Gαi1-3. Such GAP activity is not seen on Gαq/z/12/13 or Gαs (Snow et al. 1998) . Although all four RGS-R7/Gβ5 heterodimers exhibit similar activity on GαoGTP, their GAP activity on activated Gαi1, Gαi2 and Gαi3 subunits is generally weak (Hooks et al. 2003) .
RGS-R12 subfamily
This subfamily consists of three members, Rgs10, Rgs12, Rgs14 (Sierra et al. 2002) , although the proteins derived from these genes differ significantly in size and functions. RGS10 is a very small protein of 173 amino acids that exhibits many functional similarities to members of the RGS-R4 subfamily. In contrast, RGS12 and RGS14 are much larger proteins of 1,447 and 547 residues, respectively. The RGS12 is a 95-kDa protein that contains a rap binding domain (RBD) and a GoLoco homology domain in the Cterminus. Its long N-terminus also comprises a phosphotyrosine-binding (PTB) domain as well as a PDZ [PSD-95 (mammalian postsynaptic density protein), Dlg (Drosophila disc-large protein), ZO-1 (a mammalian tight junction protein)] domain. RGS14 is of 60-kDa protein with a short N-terminus and a long C-terminus, in which an RBD and a GoLoco domain are found. The so-called GoLoco motif is also present in a variety of other mammalian proteins (Hollinger et al. 2001; Kimple et al. 2001) . The signalling proteins bearing this motif specifically bind GDP-bound Gαi/o subunits, preventing both GDP release and Gβγ reassembly. Thus, the RGS12 and RGS14 proteins are potential bifunctional regulators of Gα activity. Their RGS activity can accelerate Gαi/o-associated GTPase and the GoLoco motif may exert guanine nucleotide dissociation inhibitor (GDI) activity on GαiGDP subunits (Kimple et al. 2001) , which would also negatively influence Gi-protein signalling.
RGS-Rz subfamily
The members of this subfamily are encoded by three different genes, Rgs17, Rgs19 and Rgs20, from which several isoforms are generated by alternative splicing (Barker et al. 2001; Doupnik et al. 2001) . The RGS-Rz proteins, RGSZ1 (RGS20), RGSZ2 (RGS17) and GAIP (G protein alpha subunit-interacting protein, also named RGS19), contain 210-239 amino acids and they can be found in the CNS. Flanking the RGS box domain, they have a short C-terminus of only 11 or 12 residues, while their N-terminus domain contains a cysteine string motif. Indeed, the RGSRz are the only RGS proteins with a heavily palmitoylated cysteine rich motif that aids their membrane targeting (De Vries et al. 1996) . The GAIP protein also presents an amphipatic helix in the N terminus and a PDZ binding motif in its C terminus (De Vries et al. 1998; Ross and Wilkie 2000) . The GAIP interacting protein C terminus (GIPC) is a PDZcontaining protein present in brain that forms a complex with GAIP and TrkA, providing a putative link between G proteins and receptor tyrosine kinase pathways (De Vries et al. 1998; Lou et al. 2001) . Members of the RGS-Rz subfamily also bind to the dileucine-rich region of GIPN (GAIP interacting protein N terminus), a putative E3 ubiquitin ligase that links these RGS-Rz proteins with Gα degradation (Fischer et al. 2003) .
The mRNA coding for RGS-RZ proteins has been detected in several areas of the mouse brain. While the GAIPassociated protein GIPC is distributed relatively uniform, the RGS-Rz proteins are expressed in specific regions of the CNS (Garzón et al. 2004 ). In solution assays, RGS-Rz proteins bind to activated Gαi/o/z/q subunits and with the exception of Gαq subunits, they display good GAP activity on them. They are considerably more efficient in deactivating GαzGTP subunits than Gαi/oGTP subunits, as is particularly evident for RGSZ1 protein (see Mao et al. 2004 and references therein). Interestingly, the GAP activity of RGSZ1 and RGSZ2 proteins greatly diminishes in membrane-based assays (Mao et al. 2004) .
A series of proteins containing a similar domain to the RGS core domain have also been described. These are tentatively grouped as the RA and RL subfamilies (Zheng et al. 1999; Ross and Wilkie 2000) . The RGS domains of the RA subfamily, axin and conductin, present considerable homology with those of the RGS proteins indicated above (Sierra et al. 2002) . However, these proteins do not appear to act as GAPs on activated Gα subunits. The RGS-RL subfamily includes groups of distantly related proteins that contain the RGS homology domain, e.g. the guanine nucleotide exchange factors RhoGEFs, GRKs, D-AKAP2 and PX1.
The influence of RGS proteins on the activity of agonists at mu-and delta-opioid receptors
In recent years, we studied how members of the RGS-R4, RGS-R7 and RGS-Rz regulate signalling through mu-and delta-opioid receptors in the mouse CNS. The capacity of opioids to produce antinociception is a clear and easily quantifiable parameter that permits us to detect changes in the potency and efficiency of agonists. The periaqueductal grey matter (PAG) plays a fundamental role in mediating the supraspinal analgesic effects of opioids administered via the intracerebroventricular (i.c.v.) route (Yaksh et al. 1976 ). In the mouse, these RGS proteins are expressed in this neural structure (Garzón et al. , 2004 López-Fando et al. 2005) and their involvement in opioid signalling has been documented using a knockdown approach. Thus, the expression of RGS proteins was impaired by administering the mice with antisense oligonucleotides (ODN) directed against their mRNAs. The selective knockdown of the target proteins was monitored by probing the proteins of mouse PAG membranes with the corresponding antibodies. The ODNs specifically reduced the expression of the RGS proteins without altering the levels of closely related members of the same RGS subfamily, of G proteins, or of opioid receptors (Garzón et al. , 2004 (Garzón et al. , 2005a Sánchez-Blázquez et al. 2003 .
In this way, it has been observed that proteins of the RGS-R4 subfamily modulate opioid activity by a push-pull mechanism. The RGS3 protein exerts a positive effect on the analgesia promoted by the mu agonists morphine and DAMGO, and also by the delta agonists [D-Pen 2,5 ]enkephalin (DPDPE) and [D-Ala 2 ]deltorphin II. This is revealed by a decrease in the effects of these agonists in RGS knockdown mice ( Fig. 1; Garzón et al. 2001) . While RGS2 produced a similar positive effect on the analgesia of the opioid agonists, it appears to inhibit [D-Ala 2 ]deltorphin II, whose effects augmented after RGS2 knockdown (Fig. 1) . The RGS4, RGS8 and RGS16 proteins all negatively modulate analgesia since reducing their expression augmented the effects of mu and delta agonists. RGS4 and RGS8 both affect morphine activity, and RGS4 also influences DAMGO, DPDPE and [D-Ala 2 ]deltorphin II ( Fig. 1 ; ). When RGS16 is impaired, the activity of low doses of morphine is elevated . RGS GAP activity serves to synchronize the variations in agonist-induced GPCR activation with the regulation of the target effectors. Thus, the results obtained when RGS4, RGS8 or RGS16 proteins are knocked down can be interpreted in terms of a prolonged effect of the activated GαGTP subunits on their target effectors and hence, the increase in the activity of mu and delta agonists. However, the diminished effects of the agonists when the levels of the RGS2 and RGS3 proteins are impaired indicate that these RGS proteins augment the effects of opioids by a mechanism not related to their GAP function. For example, this effect could involve the direct interaction with adenylyl cyclase reducing cAMP production (Chatterjee et al. 1997; Sinnarajah et al. 2001 ). Since activated Gαi/o/z proteins negatively regulate the production of cAMP, the inhibition promoted by RGS2 and RGS3 on the same effectors probably accounts for their positive effects on opioid analgesia.
Proteins of RGS-R7 subfamily in CNS, RGS6, RGS7, RGS9-2 and RGS11, negatively modulate the action of the mu-opioid receptor agonists morphine and DAMGO ( Fig. 2 ; Garzón et al. , 2003 Garzón et al. , 2005a Sánchez-Blázquez et al. 2005) . Thus, the knockdown of these proteins augments the potency of mu agonists and also extends the duration of their effects for longer periods. This is particularly evident for RGS9-2, although it is also seen to a lesser extent for RGS11 (Garzón et al. , 2005a . Similarly, knockdown of the RGS-R7-associated Gβ5 also enhances the activity of the mu opioids studied ( ]deltorphin II activity, it does not affect DPDPE .
Knockdown of neural members of RGS-Rz subfamily, RGS17(Z2), RGS19(GAIP) and RGS20(Z1), does not affect the activity of the delta receptor agonists, DPDPE and [D-Ala 2 ]deltorphin II (Garzón et al. 2004) . In contrast to the delta receptors, the mu receptors are capable of activating Gz proteins in PAG membranes (Garzón et al. 1997a,b) and in COS-7 cells (Belcheva et al. 2000) . Therefore, it seems that RGS-Rz proteins are only linked to mu receptors and that they reduce the amplitude and duration of morphine and DAMGO analgesia, although in notably different ways (Garzón et al. 2004; Sánchez-Blázquez et al. 2005) . When RGSZ1 expression is impaired, the analgesia produced by morphine is enhanced more than twofold at certain points of its time-course, and its effects are notably prolonged (the analgesic effect of 10 nmol morphine lasts for an additional 90 min) ( Fig. 2 ; Garzón et al. 2004 ). The regulation exerted by GAIP on mu opioid effects is similar but weaker to that of RGSZ1 (Garzón et al. 2004) .
The knockdown of the RGSZ2 protein significantly boosts and extends the antinociceptive activity of lower doses of morphine (1 and 3 nmol). At higher doses (10 nmol) the effect of this opioid is augments nearly twofold during the initial post-morphine administration period. Subsequently, this effect decreases and it remains almost constant for a period of 60 min before remitting. During this plateau period, the effect of morphine is significantly lower than Fig. 1 Effect of ODNs directed against RGS-R4 proteins on the time-course of analgesia evoked by mu-and delta-opioid receptor agonists. ODN solutions were made up in saline immediately prior to use. Each ODN treatment was performed on a different group of mice according to the following 5-day schedule: on days 1 and 2 with 1 nmol, on days 3 and 4 with 2 nmol, and on day 5 with 3 nmol Garzón et al. 2000) . On day 6 the animals were i.c.v. injected with the opioids. The response of the animals to nociceptive stimuli was determined by the warm water (52°C) tail-flick test. Antinociception was expressed as a percentage of the maximum possible effect, MPE=100×(test latency−baseline latency)/ (cut-off time (10 s) −baseline latency). The observed baseline latencies for the different groups studied were about 2 s and they were not significantly affected by the ODN treatments. For the different assays, a fixed dose of the opioid agonists were given and antinociception was assessed at various intervals after injection throughout the timecourse of its effect. The peak effect was included in the analysis: 30 min after morphine, 15 min after DAMGO, DPDPE and [D-Ala 2 ]deltorphin II. Values are mean±SEM from groups of ten to 20 mice. Statistical analysis of the results was performed by analysis of variance (ANOVA) followed by the Student-Newman-Keuls test (SigmaStat, SPSS Science Software, Erkrath, Germany). The level of significance was set at P<0.05. *Significantly different from the group that had received the control ODN-RD that produced in the control mice (Fig. 2) . These results indicate a critical influence of RGSZ2 on the control of morphine-activated Gα subunits. In this scenario, the impairment of RGSZ2 greatly increases the influence of activated GαGTP subunits at their effectors. This promotes the initial sharp increase in analgesia but also results in the rapid desensitization of some of the target effectors. Both RGSZ1 and notably GAIP probably exert a weaker influence on mu receptor-activated GαGTP subunits. The knockdown of these proteins does not promote such an intense increase in GαGTP subunits at the effectors as RGSZ2. In these circumstances, the effectors do not rapidly desensitize and the effects of mu agonists are increased during their analgesic time-courses.
In RGSZ1 and RGS9-2 knockdown mice, the duration of the effects of morphine is almost twice those observed in control mice (Garzón et al. 2004; Sánchez-Blázquez et al. 2005) . Such an increase could be due to amplifying the influence of the opioid receptor-activated GαGTP subunits on their effectors, which may be observed even after the agonists are removed from the receptor environment. However, these increases can be abolished by administering mu receptor antagonists during the intervals over which analgesia is extended (Garzón et al. 2004 ). This reveals that under normal circumstances, the agonist still acts on the mu receptors even when its analgesic effect fades out. Thus, RGSZ1 and RGS9-2 are responsible for attenuating and abbreviating the effects of opioid agonists, even during the period they are acting on the target receptors (Garzón et al. , 2004 (Garzón et al. , 2005a Sánchez-Blázquez et al. 2003 .
Desensitization of mu-opioid receptors influenced by RGS activity
Since some RGS proteins promote mu receptor desensitization during the time-course of an agonist's effect, we have explored their influence on prolonged tolerance. There have been relatively few studies on the molecular mechanisms responsible for the development of desensitization after a single opioid dose. This interesting phenomenon appears within hours of agonist administration and lasts for at least 2-3 days (Huidobro et al. 1976; . If desensitization lasts for days rather than hours, then it is better described as acute tolerance. The development of tolerance to morphine was studied in mice in which the levels of RGS proteins were reduced. Two consecutive i.c.v. administrations of 10 nmol morphine separated by 24 h lead to a profound desensitization of the mu receptors. At the time point at which the first dose of morphine has its maximal effect (30 min), the second dose produces only about 40% of the effect obtained with the initial administration. This tolerance profile is not altered by the knockdown of the RGS-R4 proteins, RGS4, RGS8 or RGS16. However, reduced levels of RGS2 or RGS3 produce a strong reduction in the effect of the first dose of morphine. The second dose produces a comparable effect to Fig. 2 Knockdown of RGS-R7, RGS-Rz and Gβ5 proteins on the time-course of analgesia evoked by morphine and delta agonists. Experimental details as in Fig. 1 that of the first, indicating that the initial administration did not reach the threshold necessary to promote acute tolerance (Fig. 3) . Indeed, the threshold dose necessary to produce acute tolerance to morphine is about three to four times greater than that required for producing detectable analgesia (Huidobro et al.1976; . The knockdown of the RGS-Rz members RGSZ1 and GAIP does not prevent the appearance of delayed tolerance to morphine. Impairing RGSZ2 expression leads to desensitization to the first dose of morphine and hence, as discussed above for RGS2 and RGS3, the second dose shows an effect similar to that of the first dose ( Fig. 3 ; Garzón et al. 2004; Sánchez-Blázquez et al. 2005) .
It is noteworthy that mice in which the levels of RGS-R7 proteins or of their partner protein Gβ5 are reduced, only mild tolerance to acute doses of morphine develops, if any ( Fig. 3 ; Garzón et al. , 2003 Garzón et al. , 2005a Sánchez-Blázquez et al. 2003 . Similarly, RGS9 knockout mice do not develop acute tolerance to morphine (Zachariou et al. 2003) . These observations indicate that RGS-R7 proteins are responsible for the desensitization to agonists that occurs during their time-course and also of the delayed tolerance (acute tolerance) that is observed later, even after a few days. On the other hand, the RGS-Rz proteins, particularly RGSZ1 and RGSZ2, protect the target effectors from being desensitized by the excessive regulatory pressure of mu receptor-activated GαGTP subunits. RGSZ2 knockdown, but not that of RGSZ1, promotes desensitization to the effects of morphine during the time-course of its activity. However, RGSZ1 and RGSZ2 knockdown facilitates the development of acute tolerance to doses of opioids that do not normally provoke such an effect (Garzón et al. 2004; Sánchez-Blázquez et al. 2005) . These effects are attributed to the desensitizing capacity of certain GαGTP subunits on their target effectors, particularly the Gαz subunits (Garzón et al. 2004; Sánchez-Blázquez et al. 2005) , which increases when RGS-Rz proteins are impaired. The knockdown of RGSZ1 augments the influence of GαzGTP at the effectors less than in RGSZ2 knockdown mice and as such, acute tolerance develops more slowly and appears as delayed tolerance.
Molecular mechanisms involved in the desensitization of mu-opioid receptors by RGS-R7 proteins Apart from their GAP activity, there is increasing evidence that RGS proteins also exhibit other regulatory properties. For example, RGS2, RGS3, RGS4 and GAIP obstruct the interaction between Gαq and phospholipase Cβ1, probably by binding activated Gαq subunits before they reach and regulate the effector (Hepler et al. 1997; Anger et al. 2004 ). Alternatively, they might influence signalling by directly interacting with effectors, as proposed for RGS4 and phospholipase Cβ1 (Zeng et al. 1998; Dowal et al. 2001) , and for RGS2 and RGS3 proteins and adenylyl cyclase (Chatterjee et al. 1997; Sinnarajah et al. 2001) . Indeed, the direct association of RGS proteins with the intracellular domains of GPCRs can help to deactivate GαGTP subunits before they regulate their corresponding effectors. This has been documented in solution assays for members of RGS-R4 subfamily and subtypes of the muscarinic acetylcholine receptors Fig. 3 Role of RGS proteins from the RGS-Rz, RGS-R7 and RGS-R4 subfamilies, and of the Gβ5 protein in the delayed tolerance that develops after administering a single dose of morphine. Saline or a priming dose of 10 nmol morphine was i.c.v. injected to mice that had been treated with ODNs directed against the RGS, or Gβ5 proteins, or with the control ODN-RD. All groups received a test i.c.v. dose of 10 nmol morphine 24 h later, and analgesia was evaluated after 30 min (the peak time for the analgesic effect of morphine). Values are the mean±SEM from groups of ten to 20 mice. For every ODN treatment, *, indicates a significant difference from the group injected with saline instead of the morphine priming dose. Φ: significantly different from the group treated with the control ODN and injected with saline before the second opioid dose. Thus, these differences are produced by the sole effect of the ODN. ANOVA-Student-NewmanKeuls test; P<0.05. Details as in Fig. 1 (Bernstein et al. 2004) , as well as for RGSZ1, RGSZ2 and RGS9-2 proteins and mu-opioid receptors in CNS (Garzón et al. 2005a,b) . When RGS proteins bind to GαGTP subunits but display little or no GAP activity on them, they effectively sequester these Gα subunits. Accordingly, the RH (RGS homology) domain of GRK2 binds to and sequesters activated Gαq subunits, thereby interfering with the regulation of phospholipase Cβ (Carman et al. 1999) . Similarly, sequestering of Gαq by RGS-Rz proteins reduces calcium mobilization (Mao et al. 2004) . Therefore, evidence is accumulating that RGS proteins can inhibit effector activation by different mechanisms, describing situations in which the Gα-mediated regulation of downstream effectors is impaired.
It was recently reported that activation of mu-opioid receptors in the CNS transfers control of Gα subunits to RGS9-2 and that this phenomenon plays a role in receptor desensitization (Garzón et al. 2005a) . In PAG membranes, 30 min and 3 h after i.c.v. injection of morphine, the coprecipitation of Gα subunits with mu receptors is reduced by up to 50%, while the association between Gα subunits and RGS9-2 proteins increases. However, 24 h after receiving morphine, the Gα subunits have left the RGS9-2 proteins and have re-associated with the mu receptors. Under these circumstances, morphine exhibits normal analgesic activity. Nevertheless, the doses of the opioid that are able to induce acute tolerance also promote the stable transfer of Gα subunits to RGS9-2 control. This is accompanied by Ser (3) To terminate effector regulation, the GTPase of the mu receptor-activated Gα subunits is accelerated by different subfamilies of RGS proteins. The RGS-R4 proteins, with the exception of RGS2 and RGS3, efficiently deactivate GαoGTP and GαiGTP subunits (Berman et al. 1996a ), but are much less effective on GαzGTP subunits (Hepler et al. 1997) . The members of RGS-Rz subfamily deactivate Gαi/ oGTP subunits in solution assays (see references in Mao et al. 2004 ) but they show a high degree of GTPase-activating proteins (GAP) selectivity for GαzGTP subunits. Efficient deactivation of GαzGTP subunits is critical to prevent desensitization of certain effectors (Garzón et al. 2004; Sánchez-Blázquez et al. 2005) . The GAP activity of the RGS-R7/β5 complexes appears to be specific for GαoGTP (Posner et al. 1999) . However, while they also bind GαiGTP and GαzGTP subunits (Saitoh et al. 1999; Rose et al. 2000; Sánchez-Blázquez et al. 2003) , they display weak or no GAP activity towards them (Snow et al. 1998) . This characteristic of RGS-R7/β5 complexes leads to sequestering of Gαi/z subunits and hence to effector antagonism. (4) The outcome is the inefficient reconstitution of the trimeric Gαβγ proteins that the mu receptor requires to propagate the morphine signal. (5) This progressive reduction in the pool of receptor-regulated G proteins causes attenuation and abbreviation of the effect of morphine during its time-course, or the effect of successive doses of the opioid (*Effect). If the dose of morphine is sufficiently high, the association between RGS-R7 proteins and sequestered Gα subunits is stabilized (Garzón et al. 2005a ) and thus, delayed mu receptor tolerance is observed for 2 or 3 days (Huidobro et al. 1976; . The knockdown or knockout of RGS-R7 proteins, or of Gβ5, greatly reduces or even abolishes mu-opioid receptor desensitization and acute tolerance to morphine does not develop (Garzón et al. , 2005a Sánchez-Blázquez et al. 2003; Zachariou et al. 2003) phosphorylation of RGS9-2 proteins which increases their co-precipitation with 14-3-3 proteins that bind proteins phosphorylated on Ser residues. Thus, the tolerance that develops following morphine administration is correlated with the retention-sequestering-of mu receptor-activated Gα subunits by RGS9-2 proteins (Fig. 4) . This multi-step process is initiated by the morphine-induced transfer of mu receptor-associated Gα subunits to the RGS9-2 proteins, followed by Ser phosphorylation of the latter and binding to 14-3-3 proteins (Garzón et al. 2005a ). This regulatory mechanism probably precedes the loss of mu receptors from the cell membrane that has been observed with other opioid agonists. Since the action of GPCR agonists increases the degradation rates of Gα subunits (Levis and Bourne1992; Wise et al. 1995) , it is possible that the retention of Gα subunits by RGS9-2 proteins precedes their degradation via the proteosome pathway. This is particularly relevant for the RGS-Rz subfamily that binds to the dileucine-rich region of a putative E3 ubiquitin ligase (GIPN), establishing a link between these RGS proteins and Gα degradation (Fischer et al. 2003) . Functional tolerance produced by single doses of opioids lasts for several days, thus the de novo synthesis of Gα subunits would help to restore the control responses (Huidobro et al. 1976; Garzón et al. 2002) .
Remarks
The GAP activity of the RGS-R4 subfamily helps to deactivate GαGTP subunits. This activity is responsible for maintaining a tight correspondence between the level of mu-opioid receptor activation by agonists and the regulation of target effectors. Both RGSZ2, and to a lesser extent, RGSZ1, are critical in controlling the activity of mu receptor-activated Gα subunits, in particular of Gαz. These subunits can promote rapid and profound desensitization of the effectors they regulate. The RGS-R7 proteins, in particular RGS9-2, abbreviate and attenuate the effects of agonists and they are also implicated in the development of the delayed tolerance observed after administration of high doses of mu opioids. These RGS-R7 proteins achieve this regulation by sequestering mu receptor-activated Gα subunits and thus promoting effector antagonism.
